Previous 10 | Next 10 |
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma - Review of preliminary interim data continues to demonstrate the absence of cardiotoxicity for Annamycin, repr...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...
Moleculin to Present at the H.C. Wainwright BioConnect Conference PR Newswire HOUSTON , Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of...
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases - Preliminary data currently demonstrate 50% of patients in first two cohorts experienced clinical activity, defined as st...
Moleculin Biotech (NASDAQ:MBRX) perks up 5.3% premarket after FDA allowed its Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 dose escalation...
Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme New US IND enables parallel development of WP1122 as a cancer therapy PR Newswire HOUSTON , Dec. 1, 2021 /PRNewswire/ -- Moleculin Bi...
Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event - Live moderated video webcast discussion among members of management and Thought Leader Sant P. Chawla, MD on Thursday, November 18th at 11:00 AM ET - PR Newswire HOUSTON , Nov. 12, 202...
Moleculin Biotech (NASDAQ:MBRX): Q3 GAAP EPS of -$0.15 beats by $0.05. Cash and cash equivalents of $75.18M. Press Release For further details see: Moleculin Biotech EPS beats by $0.05
Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update - Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 - - Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...